URINARY INCONTINENCE: WHAT PHARMACISTS SHOULD KNOW

"6 Overactive bladder (OAB) is a disorder associated with a feeling of urgency and frequency and can lead to urge incontinence if a patient has associated urinary leakage; therefore all patients with urge incontinence will have OAB, but not all patients with OAB will have urge incontinence.7 Ov...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drug Topics 2018-02, Vol.162 (2), p.23-27
1. Verfasser: Elaysky, Megan
Format: Magazinearticle
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 27
container_issue 2
container_start_page 23
container_title Drug Topics
container_volume 162
creator Elaysky, Megan
description "6 Overactive bladder (OAB) is a disorder associated with a feeling of urgency and frequency and can lead to urge incontinence if a patient has associated urinary leakage; therefore all patients with urge incontinence will have OAB, but not all patients with OAB will have urge incontinence.7 Overflow incontinence is related to an obstructed urine flow and/or bladder underactivity where an individual has a full bladder, but is unable to completely void at time of urination, which later leads to leakage (i.e. benign prostate hyperplasia).8 Functional incontinence, unlike the other forms of incontinence, occurs when an individual has issues getting to the restroom due to an external factor (i.e. dementia, immobility, etc.), but is not associated with urinary tract dysfunction.8 This article will highlight the diagnosis and treatment of UUI and OAB. Risks Factors, Cause, and Diagnosis of UUI/OAB While UUI/OAB is primarily associated with advanced age, other risk factors identified include educational status, neurologic diseases like prior stroke, elevated body mass index (BMI), recurrent urinary tract infections (UTIs), and positive metabolic screening, which factors in hypertension and diabetes diagnosis, waist-to-hip ratio, and elevated triglycerides.10-12 The specific mechanism that causes UUI/OAB is unknown, however in patients with this condition, urodynamic control is not well regulated.7 The main muscle of the bladder, the detrusor muscle, will involuntary contract-regardless of the bladder volume-which leads to the urge to urinate. First-line therapy for a functioning patient with complaints of UI is nonpharmacological therapy. Currently, there are no standard terms for "plus" or "ultra plus" to measure a "saturation point," so product choice should be based on patient comfort and cost.21 The Simon Foundation for Continence (https://simonfoundation. org/) is a valuable resource to provide to patients who cannot afford urinary pads as it provides a directory of United States diaper and absorbent products banks.22 Pharmacological Management If nonpharmacological therapy fails and prescription therapy is warranted, antimuscarinic agents should be considered in adults diagnosed with OAB/UUI without features of bladder obstruction or mixed incontinence.6 This class of medications works by antagonizing the smooth muscle receptors on the bladder, thus inhibiting the action of acetylcholine which causes bladder contraction.23 Through this mechanism, the medica
format Magazinearticle
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_reports_2002987819</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A532655682</galeid><sourcerecordid>A532655682</sourcerecordid><originalsourceid>FETCH-LOGICAL-g1639-f56fb27884b59ee5f74d865d44058429035bf69c09b42f78a55f082825dae9a83</originalsourceid><addsrcrecordid>eNptz01Lw0AQBuBFFKzV_xAUvEU2m5398BZiNcGaSJtSPIVNsttG0qRm0_9voB4qlDm8MDzvwFygiSd97goP-CWaYOwRlzGPXaMba78xxpQBnyCyWsRJsPhy4iRMkyxOZkk4e3bWUZA5n1Gw-AjCeJktnWWUruYvznuSrm_RlVGN1Xd_OUWr11kWRu48fYvDYO5uPOZL1wAzBeFC0AKk1mA4rQSDilIMghKJfSgMkyWWBSWGCwVgsCCCQKW0VMKfovvj3X3f_Ry0HfJe77t-sDnBmEjBxfjgFD0c0UY1Oq9b0w29Kne1LfMAfMIAmCCjcs-ojW51r5qu1aYe1__80xk_TqV3dXm28HhS2GrVDFvbNYeh7lp7Cn8Bd4Zyjg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>magazinearticle</recordtype><pqid>2002987819</pqid></control><display><type>magazinearticle</type><title>URINARY INCONTINENCE: WHAT PHARMACISTS SHOULD KNOW</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Elaysky, Megan</creator><creatorcontrib>Elaysky, Megan</creatorcontrib><description>"6 Overactive bladder (OAB) is a disorder associated with a feeling of urgency and frequency and can lead to urge incontinence if a patient has associated urinary leakage; therefore all patients with urge incontinence will have OAB, but not all patients with OAB will have urge incontinence.7 Overflow incontinence is related to an obstructed urine flow and/or bladder underactivity where an individual has a full bladder, but is unable to completely void at time of urination, which later leads to leakage (i.e. benign prostate hyperplasia).8 Functional incontinence, unlike the other forms of incontinence, occurs when an individual has issues getting to the restroom due to an external factor (i.e. dementia, immobility, etc.), but is not associated with urinary tract dysfunction.8 This article will highlight the diagnosis and treatment of UUI and OAB. Risks Factors, Cause, and Diagnosis of UUI/OAB While UUI/OAB is primarily associated with advanced age, other risk factors identified include educational status, neurologic diseases like prior stroke, elevated body mass index (BMI), recurrent urinary tract infections (UTIs), and positive metabolic screening, which factors in hypertension and diabetes diagnosis, waist-to-hip ratio, and elevated triglycerides.10-12 The specific mechanism that causes UUI/OAB is unknown, however in patients with this condition, urodynamic control is not well regulated.7 The main muscle of the bladder, the detrusor muscle, will involuntary contract-regardless of the bladder volume-which leads to the urge to urinate. First-line therapy for a functioning patient with complaints of UI is nonpharmacological therapy. Currently, there are no standard terms for "plus" or "ultra plus" to measure a "saturation point," so product choice should be based on patient comfort and cost.21 The Simon Foundation for Continence (https://simonfoundation. org/) is a valuable resource to provide to patients who cannot afford urinary pads as it provides a directory of United States diaper and absorbent products banks.22 Pharmacological Management If nonpharmacological therapy fails and prescription therapy is warranted, antimuscarinic agents should be considered in adults diagnosed with OAB/UUI without features of bladder obstruction or mixed incontinence.6 This class of medications works by antagonizing the smooth muscle receptors on the bladder, thus inhibiting the action of acetylcholine which causes bladder contraction.23 Through this mechanism, the medications increase bladder capacity and decrease urgency.24 Receptor antagonism can be localized to the bladder or more systemically involved dependent on the medication selected within the class.23 Various randomized control trials and reviews have demonstrated reduced symptoms and modest improvement in quality of life when using antimuscarinic therapy.25-28 Six antimuscarinic agents are available including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium; see Table 2 for medication specific information including dosing and dose adjustments, adverse drug events, and clinical pearls.</description><identifier>ISSN: 0012-6616</identifier><identifier>EISSN: 1937-8157</identifier><language>eng</language><publisher>Monmouth Junction: UBM LLC</publisher><subject>Adjustment ; Behavior modification ; Bladder ; Care and treatment ; Causes of ; Comorbidity ; Diagnosis ; Drug dosages ; Drug therapy ; Education ; Geriatrics ; Hyperplasia ; Medical diagnosis ; Patients ; Pharmacists ; Quality of life ; Smooth muscle ; Systematic review ; Urinary incontinence ; Urine ; Urogenital system ; Womens health</subject><ispartof>Drug Topics, 2018-02, Vol.162 (2), p.23-27</ispartof><rights>COPYRIGHT 2018 UBM LLC</rights><rights>Copyright UBM Americas Feb 2018</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>312,776,780,787</link.rule.ids></links><search><creatorcontrib>Elaysky, Megan</creatorcontrib><title>URINARY INCONTINENCE: WHAT PHARMACISTS SHOULD KNOW</title><title>Drug Topics</title><description>"6 Overactive bladder (OAB) is a disorder associated with a feeling of urgency and frequency and can lead to urge incontinence if a patient has associated urinary leakage; therefore all patients with urge incontinence will have OAB, but not all patients with OAB will have urge incontinence.7 Overflow incontinence is related to an obstructed urine flow and/or bladder underactivity where an individual has a full bladder, but is unable to completely void at time of urination, which later leads to leakage (i.e. benign prostate hyperplasia).8 Functional incontinence, unlike the other forms of incontinence, occurs when an individual has issues getting to the restroom due to an external factor (i.e. dementia, immobility, etc.), but is not associated with urinary tract dysfunction.8 This article will highlight the diagnosis and treatment of UUI and OAB. Risks Factors, Cause, and Diagnosis of UUI/OAB While UUI/OAB is primarily associated with advanced age, other risk factors identified include educational status, neurologic diseases like prior stroke, elevated body mass index (BMI), recurrent urinary tract infections (UTIs), and positive metabolic screening, which factors in hypertension and diabetes diagnosis, waist-to-hip ratio, and elevated triglycerides.10-12 The specific mechanism that causes UUI/OAB is unknown, however in patients with this condition, urodynamic control is not well regulated.7 The main muscle of the bladder, the detrusor muscle, will involuntary contract-regardless of the bladder volume-which leads to the urge to urinate. First-line therapy for a functioning patient with complaints of UI is nonpharmacological therapy. Currently, there are no standard terms for "plus" or "ultra plus" to measure a "saturation point," so product choice should be based on patient comfort and cost.21 The Simon Foundation for Continence (https://simonfoundation. org/) is a valuable resource to provide to patients who cannot afford urinary pads as it provides a directory of United States diaper and absorbent products banks.22 Pharmacological Management If nonpharmacological therapy fails and prescription therapy is warranted, antimuscarinic agents should be considered in adults diagnosed with OAB/UUI without features of bladder obstruction or mixed incontinence.6 This class of medications works by antagonizing the smooth muscle receptors on the bladder, thus inhibiting the action of acetylcholine which causes bladder contraction.23 Through this mechanism, the medications increase bladder capacity and decrease urgency.24 Receptor antagonism can be localized to the bladder or more systemically involved dependent on the medication selected within the class.23 Various randomized control trials and reviews have demonstrated reduced symptoms and modest improvement in quality of life when using antimuscarinic therapy.25-28 Six antimuscarinic agents are available including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium; see Table 2 for medication specific information including dosing and dose adjustments, adverse drug events, and clinical pearls.</description><subject>Adjustment</subject><subject>Behavior modification</subject><subject>Bladder</subject><subject>Care and treatment</subject><subject>Causes of</subject><subject>Comorbidity</subject><subject>Diagnosis</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Education</subject><subject>Geriatrics</subject><subject>Hyperplasia</subject><subject>Medical diagnosis</subject><subject>Patients</subject><subject>Pharmacists</subject><subject>Quality of life</subject><subject>Smooth muscle</subject><subject>Systematic review</subject><subject>Urinary incontinence</subject><subject>Urine</subject><subject>Urogenital system</subject><subject>Womens health</subject><issn>0012-6616</issn><issn>1937-8157</issn><fulltext>true</fulltext><rsrctype>magazinearticle</rsrctype><creationdate>2018</creationdate><recordtype>magazinearticle</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptz01Lw0AQBuBFFKzV_xAUvEU2m5398BZiNcGaSJtSPIVNsttG0qRm0_9voB4qlDm8MDzvwFygiSd97goP-CWaYOwRlzGPXaMba78xxpQBnyCyWsRJsPhy4iRMkyxOZkk4e3bWUZA5n1Gw-AjCeJktnWWUruYvznuSrm_RlVGN1Xd_OUWr11kWRu48fYvDYO5uPOZL1wAzBeFC0AKk1mA4rQSDilIMghKJfSgMkyWWBSWGCwVgsCCCQKW0VMKfovvj3X3f_Ry0HfJe77t-sDnBmEjBxfjgFD0c0UY1Oq9b0w29Kne1LfMAfMIAmCCjcs-ojW51r5qu1aYe1__80xk_TqV3dXm28HhS2GrVDFvbNYeh7lp7Cn8Bd4Zyjg</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Elaysky, Megan</creator><general>UBM LLC</general><general>MultiMedia Healthcare Inc</general><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RQ</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>883</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0F</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>U9A</scope></search><sort><creationdate>20180201</creationdate><title>URINARY INCONTINENCE: WHAT PHARMACISTS SHOULD KNOW</title><author>Elaysky, Megan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g1639-f56fb27884b59ee5f74d865d44058429035bf69c09b42f78a55f082825dae9a83</frbrgroupid><rsrctype>magazinearticle</rsrctype><prefilter>magazinearticle</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adjustment</topic><topic>Behavior modification</topic><topic>Bladder</topic><topic>Care and treatment</topic><topic>Causes of</topic><topic>Comorbidity</topic><topic>Diagnosis</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Education</topic><topic>Geriatrics</topic><topic>Hyperplasia</topic><topic>Medical diagnosis</topic><topic>Patients</topic><topic>Pharmacists</topic><topic>Quality of life</topic><topic>Smooth muscle</topic><topic>Systematic review</topic><topic>Urinary incontinence</topic><topic>Urine</topic><topic>Urogenital system</topic><topic>Womens health</topic><toplevel>online_resources</toplevel><creatorcontrib>Elaysky, Megan</creatorcontrib><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Career &amp; Technical Education Database</collection><collection>ABI/INFORM Collection</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Global (Alumni Edition)</collection><collection>ABI/INFORM Trade &amp; Industry (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Business Premium Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Global</collection><collection>ABI/INFORM Trade &amp; Industry</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>One Business (ProQuest)</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Drug Topics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Elaysky, Megan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>URINARY INCONTINENCE: WHAT PHARMACISTS SHOULD KNOW</atitle><jtitle>Drug Topics</jtitle><date>2018-02-01</date><risdate>2018</risdate><volume>162</volume><issue>2</issue><spage>23</spage><epage>27</epage><pages>23-27</pages><issn>0012-6616</issn><eissn>1937-8157</eissn><abstract>"6 Overactive bladder (OAB) is a disorder associated with a feeling of urgency and frequency and can lead to urge incontinence if a patient has associated urinary leakage; therefore all patients with urge incontinence will have OAB, but not all patients with OAB will have urge incontinence.7 Overflow incontinence is related to an obstructed urine flow and/or bladder underactivity where an individual has a full bladder, but is unable to completely void at time of urination, which later leads to leakage (i.e. benign prostate hyperplasia).8 Functional incontinence, unlike the other forms of incontinence, occurs when an individual has issues getting to the restroom due to an external factor (i.e. dementia, immobility, etc.), but is not associated with urinary tract dysfunction.8 This article will highlight the diagnosis and treatment of UUI and OAB. Risks Factors, Cause, and Diagnosis of UUI/OAB While UUI/OAB is primarily associated with advanced age, other risk factors identified include educational status, neurologic diseases like prior stroke, elevated body mass index (BMI), recurrent urinary tract infections (UTIs), and positive metabolic screening, which factors in hypertension and diabetes diagnosis, waist-to-hip ratio, and elevated triglycerides.10-12 The specific mechanism that causes UUI/OAB is unknown, however in patients with this condition, urodynamic control is not well regulated.7 The main muscle of the bladder, the detrusor muscle, will involuntary contract-regardless of the bladder volume-which leads to the urge to urinate. First-line therapy for a functioning patient with complaints of UI is nonpharmacological therapy. Currently, there are no standard terms for "plus" or "ultra plus" to measure a "saturation point," so product choice should be based on patient comfort and cost.21 The Simon Foundation for Continence (https://simonfoundation. org/) is a valuable resource to provide to patients who cannot afford urinary pads as it provides a directory of United States diaper and absorbent products banks.22 Pharmacological Management If nonpharmacological therapy fails and prescription therapy is warranted, antimuscarinic agents should be considered in adults diagnosed with OAB/UUI without features of bladder obstruction or mixed incontinence.6 This class of medications works by antagonizing the smooth muscle receptors on the bladder, thus inhibiting the action of acetylcholine which causes bladder contraction.23 Through this mechanism, the medications increase bladder capacity and decrease urgency.24 Receptor antagonism can be localized to the bladder or more systemically involved dependent on the medication selected within the class.23 Various randomized control trials and reviews have demonstrated reduced symptoms and modest improvement in quality of life when using antimuscarinic therapy.25-28 Six antimuscarinic agents are available including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium; see Table 2 for medication specific information including dosing and dose adjustments, adverse drug events, and clinical pearls.</abstract><cop>Monmouth Junction</cop><pub>UBM LLC</pub><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0012-6616
ispartof Drug Topics, 2018-02, Vol.162 (2), p.23-27
issn 0012-6616
1937-8157
language eng
recordid cdi_proquest_reports_2002987819
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Adjustment
Behavior modification
Bladder
Care and treatment
Causes of
Comorbidity
Diagnosis
Drug dosages
Drug therapy
Education
Geriatrics
Hyperplasia
Medical diagnosis
Patients
Pharmacists
Quality of life
Smooth muscle
Systematic review
Urinary incontinence
Urine
Urogenital system
Womens health
title URINARY INCONTINENCE: WHAT PHARMACISTS SHOULD KNOW
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T01%3A34%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=URINARY%20INCONTINENCE:%20WHAT%20PHARMACISTS%20SHOULD%20KNOW&rft.jtitle=Drug%20Topics&rft.au=Elaysky,%20Megan&rft.date=2018-02-01&rft.volume=162&rft.issue=2&rft.spage=23&rft.epage=27&rft.pages=23-27&rft.issn=0012-6616&rft.eissn=1937-8157&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA532655682%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2002987819&rft_id=info:pmid/&rft_galeid=A532655682&rfr_iscdi=true